prior treatment with BIBF 1120 or any other angiogenesis inhibitor.chemotherapy, monoclonal antibody therapy, oral targeted therapy, hormonal therapy) prior systemic therapy for ovarian cancer (e.g.In exception to this rule, the following malignancies may be included if adequately treated: non-melanomatous skin cancer, cervical carcinoma in situ, carcinoma in situ of the breast, low risk endometrial cancer other malignancy diagnosed within the past 5 years.gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug.poorly controlled diabetes mellitus or other contraindication to high dose corticosteroid therapy.serious infections in particular if requiring systemic antibiotic (antimicrobial, antifungal) or antiviral therapy, including Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV).history of a cerebral vascular accident, transient ischemic attack or subarachnoid haemorrhage within the past 6 months. clinically relevant pericardial effusion.known inherited or acquired bleeding disorder.pre-existing sensory or motor neuropathy Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or higher, except due to trauma.clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition or hydration.clinically relevant non-healing wound, ulcer or bone fracture.planned surgery within 124 weeks after randomisation in this trial, including interval debulking surgery.histologic diagnosis of a benign or borderline tumour or of a malignant tumour of non-epithelial origin of the ovary, the fallopian tube or the peritoneum.planned application of first dose of chemotherapy after wound healing, but no later than 10 weeks after surgery.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |